Factor X deficiency.

Area of Science:

• Hematology
• Genetics
• Rare Diseases

Background:

• Factor X (FX) deficiency is a rare, autosomal recessive bleeding disorder affecting 1 in 1,000,000 people, accounting for 10% of rare bleeding diseases.
• Clinical manifestations include severe bleeding, such as hemarthroses, hematomas, and gastrointestinal or central nervous system hemorrhages.
• Diagnosis relies on prolonged prothrombin time and activated partial thromboplastin time, with classification into Type I (low FX antigen and activity) and Type II (low activity, normal/borderline antigen).

Purpose of the Study:

• To review the characteristics of Factor X deficiency.
• To discuss diagnostic approaches and genetic underpinnings.
• To evaluate current and emerging treatment strategies.

Main Methods:

• Review of literature on Factor X deficiency.
• Analysis of diagnostic criteria and genetic mutations in the F10 gene.
• Assessment of therapeutic options, including fresh-frozen plasma, prothrombin complex concentrates (PCCs), and novel FX concentrates.

Main Results:

• Factor X deficiency presents with severe bleeding symptoms and is diagnosed via coagulation tests.
• Genetic analysis reveals 105 identified mutations in the F10 gene, predominantly missense mutations.
• Current treatments like PCCs pose risks due to undefined factor concentrations; a new concentrate with defined FX and FIX levels has been developed.

Conclusions:

• Factor X deficiency is a severe bleeding disorder requiring careful diagnosis and management.
• Existing treatments have limitations and potential risks.
• Emerging therapeutic concentrates offer a potentially safer alternative for managing Factor X deficiency.